Upcoming Events and Webinars
Dr. Rakesh Nagarajan
Dr. Eric Loo
Assistant Professor, Dartmouth-Hithcock
PierianDx will present at Executive War College
May 2, 7:00-7:50 AM
Do you want real-world advice for how to effectively bring next generation sequencing (NGS) tests into your hospital lab? Then plan to attend our informative presentation at Executive War College:
Bringing Next Generation Sequencing (NGS) Tests into Your Hospital Lab
Dr. Rakesh Nagarajan, CEO, PierianDx, and Dr. Eric Loo, Assistant Professor, Dartmouth-Hithcock, will discuss how to overcome challenges associated with bringing NGS testing into a hospital setting. During the workshop, you will learn how to:
Design and implement an end-to-end workflow solution from raw sequencing data, through analysis and final clinical report.
Plan for and implement NGS testing.
Strike a balance between machine learning technology and human clinical expertise to advance NGS testing.
Build upon best practices from academic medical centers, health systems, and cancer centers that have already expanded their programs and improved outcomes for patients.
Navigate CLIA and CAP guidelines to achieve compliance.
Build the business case and realize benefits for insourcing your molecular testing, including reimbursement approaches.
SVP Business Development
Optimizing the Bioinformatics Output of Your Molecular Pathology Lab with the Right Mix of Technology and Services
Tuesday, April 24, 2018 – 2 pm CST
If you are a clinical lab looking to build or accelerate your NGS testing capability where do you start? The components of success can be overwhelming – planning, assay design, validation, clinical lab workflow, informatics, and interpretation. Additionally, deciding the right balance between technology that leverages Artificial Intelligence (AI) and the clinical team needed to make it happen can be confusing at best.
During this one-hour webinar, BG Jones, SVP of Business Development for PierianDx, who has 23 years of experience in healthcare IT and genomics technology, will demonstrate how to pull it all together using “Actionable Intelligence” – a combination of machine learning and human expertise to achieve clinically actionable insights.
He will discuss designing and implementing an end-to-end workflow solution from raw sequencing data, through analysis and final clinical report. BG will provide customer examples that demonstrate the benefits of PierianDx’s leading clinical genomics technology platform, the Clinical Genomics WorkSpace, and the wide range of services available.
Learn how to develop the right approach to planning and implementing molecular testing in your lab.
Be introduced the spectrum of PierianDx services that complement our technology, including: precision medicine planning, assay selection, physician engagement, validation, technology integration, interpretation and lab services.
Understand the benefits of PierianDx’s Actionable Intelligence engine, a constantly learning knowledgebase of millions of biomedical findings.
Discover real-world examples of how academic medical centers, health systems, and cancer centers have implemented best practices to expand their programs and improve outcomes for patients.
To register for the webinar go to: Register for Webinar
PierianDx to Exhibit at ACMG 2018
PierianDx will highlight germline features of its genomics technology platform at the American College of Medical Genetics and Genomics (ACMG) annual meeting April 10-14 in Charlotte, North Carolina.
Representatives from PierianDx will be on hand in Booth 1203 demonstrating the Clinical Genomics WorkSpace (CGW), the industry’s leading integrated workspace for genomic analytics, classification, interpretation and reporting.
CGW germline testing features include phenotype-based prioritization of variants and rapid classification of variants following ACMG guidelines. PierianDx’s support for germline testing also includes Clinical Microarray (CMA), commonly used in the germline setting to evaluate complex development disorders.
PierianDx complements its germline technology with a range of support services. The company’s interpretation services involves clinical and scientific teams leveraging CGW’s patented knowledgebase to provide highly scalable and reliable clinical interpretations for inherited diseases. Interpretations by PierianDx variant scientists and medical directors are combined with machine learning within the knowledgebase comprised of million of biomedical finding to produce the most clinically actionable insight available for customers.
If you would like to learn more about PierianDx or CGW, please schedule a meeting during ACMG.
PierianDx Hosts Expert Customer Panel Discussion Regarding Debated CMS National Coverage Decision on NGS Testing
February 22, 2018
Dr. Rakesh Nagarajan
PierianDx CEO, Dr. Rakesh Nagarajan, and Medical Director, Dr. Shalini Verma, recently posted their perspectives on the CMS website (See Comments). On February 22 at 2 pm CST, Dr. Nagarajan and Dr. Verma will facilitate a roundtable discussion among representatives from NorthShore University Health System, Moffitt Cancer Center, UVA Health System, the Medical College of Georgia at Augusta University, and the University of Vermont Health System.
The panel discussion will focus on how the proposal to limit the coverage to only FDA approved NGS tests with companion diagnostic indications could impose restrictive criteria for coverage with development, making explicit a policy of non-coverage for NGS tests if the test does not meet criteria listed in the proposed NCD. For academic centers, leading cancer institutions, and essential community cancer centers that have CLIA-certified laboratories providing validated laboratory developed NGS-based tests, the policy would supersede existing local coverage policies for most of those tests and limit Medicare beneficiaries’ access to a single test.
Featuring Speakers from:
Ravindra Kolhe, MD, PhD, Director, Georgia Esoteric & Molecular Laboratory at Augusta University
Karen L. Kaul, MD, PhD, Chairman of the Department of Pathology, NorthShore University Health System
Theresa Ann Boyle, MD, PhD, Molecular Genetic Pathologist at Moffitt Cancer Center
Mani S. Mahadevan, M.D., Professor of Pathology Medical Director of Molecular Diagnostics Laboratory at UVA Health System
Nikoletta Sidiropoulos, M.D., Director of the University of Vermont Health System Genomics Medicine Laboratory
Precision Oncology Roundtable: Ask the Experts about NGS-based Tumor Profiling
October 12, 2017
Featuring Speakers from:
Moffitt Cancer Center
This webinar was an interactive roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.
Our expert panel — Gregory Tsongalis from Dartmouth-Hitchcock, Anthony Magliocco from Moffitt Cancer Center, Ravindra Kolhe from Augusta University, and Rakesh Nagarajan from PierianDx — will specifically discuss their experiences with Illumina’s TruSight Tumor 170 targeted cancer assay.
The TST170 next-generation sequencing-based panel targets single nucleotide variants, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes and also calculates metrics such as tumor mutation burden and determines evidence for microsatellite instability.
Our panelists will discuss the design of the assay, data analytics, and reasons behind their selection of the TST170 assay, and will share details of how it is being utilized within their organizations.
Dr. Rakesh Nagarajan
Clinical Genomicist Workspace (CGW): Accelerate Your NGS Testing with an End-to-End Integrated Workspace
September 28, 2017
PierianDx accelerates precision medicine by offering one space to handle a range of genomic testing, from somatic to constitutional, from small panels to whole exome or genome. During this webinar, PierianDx Chief Biomedical Informatics Officer Dr. Rakesh Nagarajan will provide an overview of CGW and illustrate how the industry leading platform seamlessly manages genomic data and workflow for each case, from variant analysis and classification to interpretation, reporting and final sign out. Nagarajan will discuss:
An overview of CGW key features and functions
How PierianDx’s knowledgebase helps to deliver clinically actionable results by leveraging millions of biomedical findings across multiple databases to analyze and classify each detected variant
Examples of actionable clinical reports, both somatic and constitutional
Customer case studies and how CGW has accelerated NGS testing programs, streamlined lab efficiencies and ultimately improved patient care
Dr. Rakesh Nagarajan
Building a Best-in-Class Precision Medicine Program: The Moffitt Cancer Center Story
September 14, 2017
Building a world-class precision medicine program takes the right mix of innovative leadership, advanced technology, clinical acumen, and strategic partnerships. During this webinar, Dr. Anthony Magliocco, the Chair of Anatomic Pathology at Moffitt Cancer Center, will share the Moffitt success story – from its pioneering inception to being one of only 47 Comprehensive Cancer Centers as designated by the National Cancer Institute.
Dr. Magliocco will discuss:
Key variables that played an important part in Moffitt Cancer Center’s evolution.
The role of the state-of-the-art Morsani Molecular Diagnostics Laboratory played in that evolution
Pathways to success, unexpected barriers, and an in-depth review of what steps were taken to ensure that the patient comes first
A blueprint for other clinical labs seeking to accelerate precision medicine and NGS testing
Dr. Rakesh Nagarajan
Taking Your NGS Testing Program to the Next Level with Enhanced Validation and Interpretation Services
July 13, 2017 at 11:00am CST
The success of any precision medicine program involves the right combination of personnel and technology. PierianDx’s Clinical Genomicist Workspace (CGW) has been the technology platform of choice for clinical labs to seamlessly manage their genomic data and workflow from variant analysis and classification to interpretation, reporting and final sign out. However, the right strategy and clinical resources at the validation and interpretation stages are just as important to that success. During this webinar, PierianDx Chief Bioinformatics Officer Rakesh Nagarajan will discuss ways clinical labs can improve validation and interpretation approaches to enhance report actionability, relevance and throughput. Specifically, Nagarajan will discuss:
Guidelines for improved test validation covering a range of examples
Various validation reports, covering a range of different assays
Understanding the different roles of automated interpretation and clinical interpretation utilizing genomic scientists and medical directors
Case studies of customers who have enhanced their clinical lab capability with PierianDx validation and interpretation services
Dr. Nikoletta Sidiropoulos
Accelerating Your NGS Testing Program: Examples and Case Studies
On March 9th, Clinical Genomicist Workspace user and Partner Sharing Network contributor, Dr. Nikoletta Sidiropoulos from University of Vermont Medical Center hosted a webinar with PierianDx exploring various ways clinical labs have established or expanded their NGS testing programs by implementing improved workflow and clinical integration into their organization. Dr. Sidiropoulos shared her experiences and lessons learned as she works to evolve the university’s precision medicine program. Specific examples were shared on how to improve clinical lab workflow, starting with DNA or RNA samples and ending with a report of relevant variants to assist in clinical decision-making. By the end of this webinar, participants will have some real-world examples of how to accelerate their own personalized medicine initiatives from clinical experts in the field.
NGS Roundtable: Ask the Experts about the Future of Clinical NGS Testing
This interactive roundtable discusses established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting. An expert panel of leading pathologists, medical geneticists, and researchers will address genomic testing advances in two thematic areas: 1) scientific and clinical trends in reporting, and 2) clinical lab operations and quality management.
Topics covered by the expert panel include the importance of proficiency testing, both from the regulatory and quality perspective, and technical and clinical advances in using NGS to predict effective immunotherapy and determine tumor mutation load.